• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Moberg Pharma

10.30 SEK

+11.47 %

Less than 1K followers

MOB

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+11.47 %
-3.74 %
-1.90 %
+0.29 %
+10.75 %
+20.47 %
-21.97 %
-69.23 %
-82.76 %

Moberg Pharma is a Swedish pharmaceutical company with a focus on commercialization of proprietary drugs based on proven substances. The company works primarily in nail fungus, where Moberg Pharma is developing a topical treatment. Moberg Pharma has agreements with commercial partners in place in Europe and Canada, among other places. The company's headquarters are located in Bromma.

Read more
Market cap
501.73M SEK
Turnover
1.93M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Forum discussions
Moberg Pharma Sidan kunde inte hittas Page not found A major blow: according to preliminary data, the drug’s efficacy is weaker than expected. The press release still leaves some things open to speculation, but the market has already drawn its conclusions.
9/13/2024, 7:55 AM
by Clark kent
7
Interim Report May 7th Moberg Pharma Sidan kunde inte hittas Page not found Some sales are already happening in Sweden. Marketing authorizations have now been received in all 13 EU countries that participated in the licensing process, and Terclara is coming to market over-the-counter...
5/9/2024, 9:32 AM
by Makee
5
A press release was issued yesterday stating that sales have (finally) started in Sweden and it’s apparently available in most pharmacies now. Sidan kunde inte hittas | Moberg Pharma. It is also available for order from online pharmacies without a prescription, and the price seems...
2/8/2024, 4:48 PM
by Makee
5
The conference call recording has now been published on Moberg’s website: Sidan kunde inte hittas | Moberg Pharma In my opinion, it didn’t provide much additional information: -They are not publishing patient numbers or percentages because they want to “protect” the blinded data ...
9/13/2024, 3:56 PM
by Makee
3
We should think about this from the customer’s, i.e., the patient’s, perspective. They notice that the “nail is ugly.” The doctor sees the same thing. They consider whether the nail is damaged or if there is fungus. A culture is taken. The result is positive, and treatment begins...
1/2/2024, 1:05 PM
by Vino Pino
3
After the USA disappointment, the strategy is now the EU. The market has punished. Jan-Mar Oct-Dec Jul-Sep Apr-Jun Jan-Mar 2025 2024 2024 2024 2024 values in thousands SEK Net revenue 3,869 1,027 3,855 4,109 820 Cost of goods sold -1,304 -1,165 -615 -1,388 -328 Gross profit 2,565...
5/21/2025, 7:49 AM
by Clark kent
2
It could very well be an alternative. In your table, the figures do not convince me of its superiority. By the appearance of the nail, I meant how it looks after the treatment, i.e., it hasn’t healed. As an additional problem, it is mentioned there that terbinafine discolors the ...
1/2/2024, 3:14 PM
by Vino Pino
2
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13.8.
2026

Interim report Q2'26

12.11.
2026

Interim report Q3'26

Regulatory press release6/18/2026, 1:00 PM

Moberg Pharma: The board of directors exercises authorizations to issue and repurchase C-shares, and converts class C shares to common shares

Moberg Pharma
Press release6/15/2026, 6:00 AM

Moberg Pharma reports progress on commercial launch preparations

Moberg Pharma
Regulatory press release6/8/2026, 6:00 AM

Moberg Pharma and Karo Healthcare expand collaboration for MOB-015/Terclara to China

Moberg Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release5/21/2026, 1:00 PM

Bulletin from Moberg Pharma's AGM on May 21[st], 2026

Moberg Pharma
Press release5/13/2026, 9:56 AM

Redeye: Moberg Pharma (Q1 Review): APAC Expansion strengthens long-term growth case

Moberg Pharma
Regulatory press release5/12/2026, 6:00 AM

Interim report January - March 2026

Moberg Pharma
Regulatory press release4/24/2026, 10:00 AM

Moberg Pharma and Karo Healthcare expand collaboration for MOB-015/Terclara to Australia, New Zealand, South Korea and Taiwan

Moberg Pharma
Regulatory press release4/17/2026, 6:01 AM

Notice of Annual General Meeting in Moberg Pharma AB (publ)

Moberg Pharma
Regulatory press release4/17/2026, 6:00 AM

Moberg Pharma Annual Report 2025

Moberg Pharma
Regulatory press release3/13/2026, 2:00 PM

Moberg Pharma: Additional terbinafine supplier approved

Moberg Pharma
Press release2/19/2026, 12:38 PM

Redeye: Moberg Pharma (Q4 Review): Solid ending to a breakthrough year

Moberg Pharma
Regulatory press release2/17/2026, 7:00 AM

Moberg Pharma Year-end report 2025

Moberg Pharma
Press release11/14/2025, 11:32 AM

Redeye: Moberg Pharma (Q3 Review) - European footprint expanded, strengthening mid-/long-term outlook

Moberg Pharma
Regulatory press release11/11/2025, 7:00 AM

Moberg Pharma interim report January - September 2025

Moberg Pharma
Regulatory press release11/5/2025, 7:30 AM

Moberg Pharma and Karo Healthcare enter exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential

Moberg Pharma
Regulatory press release10/31/2025, 7:30 AM

Moberg Pharma's Nomination Committee appointed

Moberg Pharma
Regulatory press release9/29/2025, 12:00 PM

Bulletin from Moberg Pharma's Extraordinary General Meeting held on 29 September 2025

Moberg Pharma
Regulatory press release9/3/2025, 6:00 AM

Notice of extraordinary general meeting in Moberg Pharma AB (publ)

Moberg Pharma
Press release9/3/2025, 5:59 AM

Moberg Pharma to Expand Board of Directors and Withdraw Share Issue Authorization

Moberg Pharma
Press release8/13/2025, 9:48 AM

Redeye: Moberg Pharma - Terclara is the market leader in both Sweden and Norway

Moberg Pharma